Pliant Therapeutics, Inc. (PLRX)
Total Valuation
PLRX has a market cap or net worth of $849.33 million. The enterprise value is $337.80 million.
| Market Cap | 849.33M |
| Enterprise Value | 337.80M |
Important Dates
The last earnings date was Thursday, November 9, 2023, after market close.
| Earnings Date | Nov 9, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
PLRX has 59.90 million shares outstanding. The number of shares has increased by 27.54% in one year.
| Shares Outstanding | 59.90M |
| Shares Change (YoY) | +27.54% |
| Shares Change (QoQ) | +0.87% |
| Owned by Insiders (%) | 5.93% |
| Owned by Institutions (%) | 98.02% |
| Float | 44.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 239.58 |
| Forward PS | 689.11 |
| PB Ratio | 1.69 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 95.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.51, with a Debt / Equity ratio of 0.02.
| Current Ratio | 19.51 |
| Quick Ratio | n/a |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -88.35 |
Financial Efficiency
Return on equity (ROE) is -32.50% and return on invested capital (ROIC) is -33.88%.
| Return on Equity (ROE) | -32.50% |
| Return on Assets (ROA) | -30.10% |
| Return on Capital (ROIC) | -33.88% |
| Revenue Per Employee | $22,296 |
| Profits Per Employee | -$976,648 |
| Employee Count | 159 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.13% in the last 52 weeks. The beta is 1.25, so PLRX's price volatility has been higher than the market average.
| Beta (1Y) | 1.25 |
| 52-Week Price Change | -27.13% |
| 50-Day Moving Average | 15.08 |
| 200-Day Moving Average | 20.88 |
| Relative Strength Index (RSI) | 47.73 |
| Average Volume (30 Days) | 574,238 |
Short Selling Information
The latest short interest is 6.34 million, so 10.58% of the outstanding shares have been sold short.
| Short Interest | 6.34M |
| Short Previous Month | 6.48M |
| Short % of Shares Out | 10.58% |
| Short % of Float | 14.26% |
| Short Ratio (days to cover) | 11.01 |
Income Statement
In the last 12 months, PLRX had revenue of $3.55 million and -$155.29 million in losses. Loss per share was -$2.79.
| Revenue | 3.55M |
| Gross Profit | 3.55M |
| Operating Income | -174.51M |
| Pretax Income | -155.29M |
| Net Income | -155.29M |
| EBITDA | -149.29M |
| EBIT | -153.55M |
| Loss Per Share | -$2.79 |
Balance Sheet
The company has $523.61 million in cash and $12.08 million in debt, giving a net cash position of $511.53 million or $8.54 per share.
| Cash & Cash Equivalents | 523.61M |
| Total Debt | 12.08M |
| Net Cash | 511.53M |
| Net Cash Per Share | $8.54 |
| Equity / Book Value | 503.05M |
| Book Value Per Share | 8.40 |
| Working Capital | 506.94M |
Cash Flow
In the last 12 months, operating cash flow was -$122.50 million and capital expenditures -$1.03 million, giving a free cash flow of -$123.52 million.
| Operating Cash Flow | -122.50M |
| Capital Expenditures | -1.03M |
| Free Cash Flow | -123.52M |
| FCF Per Share | -$2.07 |
Margins
Gross margin is 100.00%, with operating and profit margins of -4,922.65% and -4,380.45%.
| Gross Margin | 100.00% |
| Operating Margin | -4,922.65% |
| Pretax Margin | -4,380.45% |
| Profit Margin | -4,380.45% |
| EBITDA Margin | -4,211.17% |
| EBIT Margin | -4,331.42% |
| FCF Margin | -3,484.46% |
Dividends & Yields
PLRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -18.28% |
| FCF Yield | -14.54% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.54% |
| Shareholder Yield | -27.54% |
Analyst Forecast
The average price target for PLRX is $48.45, which is 241.68% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $48.45 |
| Price Target Difference | 241.68% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 41.80% |
| EPS Growth Forecast (5Y) | 2.35% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PLRX has an Altman Z-Score of 12.63 and a Piotroski F-Score of 3.
| Altman Z-Score | 12.63 |
| Piotroski F-Score | 3 |